Mapping the Future: Identifying High-value Therapy Area Strategy for Emerging Markets
Background: In an evolving global disease landscape, identifying the right therapy areas or indication setting for investment is a strategic move that defines a company’s growth trajectory, especially in emerging markets where potential is enormous but super fragmented. Our biopharma client, a global player aiming to expand their footprint in Asia-Pacific and Latin America, needed a reliable way to make informed, data-based decisions on where to focus its R&D and commercial resources. Thelansis partnered with the client, leveraging its disease-area gold-standard disease burden data and market intelligence to help them pinpoint high-growth therapy areas and align their R&D priorities with market needs. The client faced three key challenges: Scattered data sources with inconsistent disease and market reporting across countries. Limited visibility into disease burden trends and treatment landscape in rapidly evolving markets. Lack of an integrated framework...